About the Presenters
Join analysts from Decision Resources Group for expert analysis around the leading issues and latest developments around cardiovascular. Our presenters include:
James Avallone is a Principal Analyst for Manhattan Research, and specializes in physician digital trends and strategies. Prior to joining Manhattan Research, James worked as a Senior Journalist at BioPharm Insight, a subsidiary of the Financial Times. Here James did in-depth analysis and coverage on digital trends in the physician community, novel medical devices and pharmaceutical drug development. Prior to this James worked at the Lineberger Comprehensive Cancer Center at the University of North Carolina as an oncology researcher, helping to develop non-Hodgkin’s lymphoma treatments. James graduated from UNC-Chapel Hill with honors.
Karene Dumoulin is Manager of Business Development at Millennium Research Group. She has extensive experience in financial and strategic planning and analysis and has worked across several product lines at MRG to develop the cardiovascular product offering. Prior to joining MRG, Karene worked in finance and strategic marketing roles for Boston Scientific Europe. Karene has a Bachelor of Commerce from Queen’s University in Canada.
Graeme Green, M.Sc., Ph.D., is a senior analyst in the cardiovascular and metabolic diseases division at Decision Resources. Prior to joining Decision Resources he was a research consultant for a financial management consultancy and research house. Dr. Green completed a Ph.D. in molecular medical microbiology at King’s College London and also holds an M.Sc. in forensic science and a B.Sc. in biomedical sciences (with a specialization in pharmacology), both also from King’s College.
Michael Hughes, M.Sc., Ph.D., is principal epidemiologist of Decision Resources. Before joining Decision Resources, he worked as the research fellow and project manager on behalf of NICE in London for the development of the national guidelines for atrial fibrillation and hypertension. More recently he has worked as a research fellow on behalf of the American College of Chest Physicians for the updated guidelines on antithrombotic therapy. Dr. Hughes was co-author for the chapter on stroke prevention in atrial fibrillation in the ACCP guidelines on antithrombotic therapy. He holds a Ph.D. in Measurement and Information in Medicine from City University, London.
Matthew Killeen, Ph.D., is an Associate Consultant in the Decision Resources strategy consulting practice where he specializes in performing product opportunity assessments and landscaping global medical practice patterns in a range of CV indications. Dr. Killeen is an expert on drug safety; he has authored a book on the role of cardiac safety on pharmaceutical development, co-chaired a symposium at the FDA, and spoken at several FDA and industry conferences. Prior to joining the company, Dr. Killeen worked in life sciences business development for a technology transfer consultancy, and in drug discovery for Eli Lilly. Dr. Killeen has authored over 20 peer-reviewed articles on topics including atrial fibrillation, cardiac safety, and ventricular arrhythmias. Dr. Killeen holds a Ph.D. in Cardiac Electrophysiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds. Additionally, he has held cardiology research fellowships at Harvard Medical School and the Massachusetts General Hospital.
Adrienne Lovink is Vice President of Consulting at Millennium Research Group. Previously, Adrienne was the Manager of the Cardiovascular division, where she oversaw the completion of more than 100 projects. Adrienne’s specific areas of focus are due diligence projects, conjoint, customer loyalty and behavior and the peripheral vascular and transcatheter embolization and occlusion markets. Prior to joining MRG, Adrienne spent several years as a research scientist for a leading pharmaceutical company. Adrienne finished first in her class with a BASc in Engineering from the University of Toronto. She also holds a graduate degree from the Institute of Biomaterials and Biomedical Engineering.
Ken McLaren is Chief Operating Officer of Millennium Research Group. Previously, Ken held roles of Vice President of Strategic Initiatives, Vice President of Products, Vice President of Marketrack and Manager of the Cardiovascular analyst team. His teams have been responsible for the evolution of MRG products and services, and the commercialization of new MRG products such as Procedure Finder and Perception Pulse. Ken started with MRG in 2003 as a market analyst and has written numerous market reports in addition to leading multiple custom consulting projects for the industry's key players. Ken holds a BASc in Engineering Science from the University of Toronto.
Nikhil Mehta, M.Eng., is Therapeutic Area Director for cardiovascular disorders at Decision Resources Group. During his eight years at Decision Resources, Mr. Mehta has specialized in analyzing markets for dyslipidemia, coronary heart disease, pulmonary arterial hypertension, and indications for antithrombotic therapy, including venous thromboembolism, acute coronary syndrome, and atrial fibrillation. He graduated from University College London and Rensselaer Polytechnic Institute with a Master's degree in biochemical engineering, and has experience in bioprocess development at Pfizer Global R&D in Connecticut prior to joining Decision Resources.
Benjamin M. Scirica, M.D., M.P.H.,
is currently an Investigator at the TIMI Study Group (an academic research organization that has performed over 50 clinical trials in atherosclerotic heart disease), an attending cardiologist, Director of Quality Initiatives and an Assistant Professor of Medicine at Harvard Medical School.
His research interests center on the identification and application of novel cardiac biomarkers and electrocardiographic techniques. He is the Director of the TIMI ECG Core Laboratory, which had analyzed over 20,000 continuous and static ECGs from multiple trials in acute coronary syndromes including the ExTRACT-TIMI 25, CLARITY-TIMI 28, DISPERSE2, PLATO, and MERLIN-TIMI 36 trials. He is Principal Investigator of AVANT GARDE-TIMI 43 trial and Co-investigator of MERLIN-TIMI 36 trial, TRA 2Pº-TIMI 50 trials, and SAVOR-TIMI 53.
Dr. Scirica has authored or co-authored over 70 peer-reviewed articles, serves the on Editorial Board of ACCEL and is a reviewer for multiple journals including Lancet, Circulation and JACC. He practices general cardiology in the Cardiac Care Unit, cardiology in-patient service and the Watkins Cardiovascular Clinic at Brigham and Women’s Hospital.
He graduated from Harvard Medical School and trained in Internal Medicine and Cardiovascular Medicine at Brigham and Women's Hospital. He has a Master's of Public Health degree from Harvard School of Public Health.
The seminar will feature analysis from products from the following companies:
View detailed agenda ...